Benperidol for schizophrenia

Leucht, Stefan; Hartung, Benno

doi:10.1002/14651858.cd003083.pub2

Cited by 3 publications

(2 citation statements)

References 35 publications

(17 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…41,44−46 Hence, numerous efforts have been made over the years to create new techniques for the synthesis of piperidine-containing molecules. 47 Currently, Food and Drug Administration (FDA)-approved drugs, such as antipsychotics, include haloperidol, 48 benperidol, 49 risperidone, 50 and thioridazine 51 for the symptomatic management of schizophrenia; droperidol, a dopamine antagonist used to prevent and treat postoperative nausea and vomiting; 52 and anticholinesterases, including donepezil 53 for treating AD (Figure 3). 26 Recently, many structural scaffolds, such as chalcones, 54 conjugated dienones, 55 isatins, 56 chromones, 57 coumarins, 58 pyrazolines, 59 quinazolines, 60 β-carbolines, 61 and benzyloxyderived molecules, 62 are used to develop MAO inhibitors.…”

Section: Introductionmentioning

confidence: 99%

“…Currently, Food and Drug Administration (FDA)-approved drugs, such as antipsychotics, include haloperidol, 48 benperidol, 49 risperidone, 50 and thioridazine 51 for the symptomatic management of schizophrenia; droperidol, a dopamine antagonist used to prevent and treat postoperative nausea and vomiting; 52 and anticholinesterases, including donepezil 53 for treating AD ( Figure 3 ). 26 …”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Piperidine: A Versatile Heterocyclic Ring for Developing Monoamine Oxidase Inhibitors

Jayan,

Chandran,

Thekkantavida

et al. 2023

ACS Omega

View full text Add to dashboard Cite

The monoamine oxidase enzyme (MAO), which is bound on the membrane of mitochondria, catalyzes the oxidative deamination of endogenous and exogenous monoamines, including monoamine neurotransmitters such as serotonin, adrenaline, and dopamine. These enzymes have been proven to play a significant role in neurodegeneration; thus, they have recently been researched as prospective therapeutic targets for neurodegenerative illness treatment and management. MAO inhibitors have already been marketed as neurodegeneration illness treatments despite their substantial side effects. Hence, researchers are concentrating on developing novel molecules with selective and reversible inhibitory properties. Piperine, which is a phytochemical component present in black pepper, has been established as a potent MAO inhibitor. Piperine encompasses a piperidine nucleus with antibacterial, anti-inflammatory, antihypertensive, anticonvulsant, antimalarial, antiviral, and anticancer properties. The current Review focuses on the structural changes and structure–activity relationships of piperidine derivatives as MAO inhibitors.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Piperidine: A Versatile Heterocyclic Ring for Developing Monoamine Oxidase Inhibitors

Jayan,

Chandran,

Thekkantavida

et al. 2023

ACS Omega

View full text Add to dashboard Cite

show abstract

Benperidol for schizophrenia

Leucht

Hartung

2005

Cochrane Database of Systematic Reviews

Self Cite

View full text Add to dashboard Cite

BackgroundBenperidol is a relatively old antipsychotic drug that has been marketed since 1966. It has been used in Germany for 30 years but is also available in Belgium, Greece, Italy, the Netherlands and the UK. Benperidol is a butyrophenone antipsychotic, with the highest neuroleptic potency in terms of D2 receptor blockade. Those taking it are therefore reputed to be at high risk of extrapyramidal side-e ects, but benperidol's unusual profile may render it valuable to certain subgroups of people with schizophrenia. ObjectivesTo examine the clinical e ects and safety of benperidol for those with schizophrenia and schizophrenia-like psychoses. Search methodsWe searched the Cochrane Schizophrenia Group's register (March 2009) for this update. Selection criteriaWe included all randomised controlled trials that compared benperidol with other treatments for people with schizophrenia, or schizophrenia-like psychoses. Data collection and analysisWe reliably selected studies, quality rated them and extracted data. We independently extracted data but excluded data if loss to follow up was greater than 50%. For dichotomous data, we estimated relative risks (RR), with the 95% confidence intervals (CI). Where possible, we calculated the number needed to treat/harm statistic (NNT/H) and used intention-to-treat analysis.Benperidol for schizophrenia (Review)

show abstract

Pharmacological Treatment for Pedophilic Disorder and Compulsive Sexual Behavior Disorder: A Review

Landgren

Savard

Dhejne

et al. 2022

Drugs

View full text Add to dashboard Cite

Guidelines for the pharmacological treatment of paraphilic disorders have historically been based on data from forensic settings and on risk levels for sexual crime. However, emerging treatment options are being evaluated for individuals experiencing distress because of their sexual urges and preferences, targeting both paraphilic disorders such as pedophilic disorder (PeD) and the new diagnosis of compulsive sexual behavior disorder (CSBD) included in the International Classification of Diseases, 11th Revision (ICD-11). As in other mental disorders, this may enable individualized pharmacological treatment plans, taking into account components of sexuality (e.g. high libido, compulsivity, anxiety-driven/sex as coping), medical and psychiatric comorbidity, adverse effects and patient preferences. In order to expand on previous reviews, we conducted a literature search focusing on randomized controlled trials of pharmacological treatment for persons likely to have PeD or CSBD. Our search was not restricted to studies involving forensic or criminal samples. Twelve studies conducted between 1974 and 2021 were identified regardless of setting (outpatient or inpatient), with only one study conducted during the last decade. Of a total of 213 participants included in these studies, 122 (57%) were likely to have PeD, 34 (16%) were likely to have a CSBD, and the remainder had unspecified paraphilias (40, 21%) or sexual offense (17, 8%) as the treatment indication. The diagnostic procedure for PeD and/or CSBD, as well as comorbid psychiatric symptoms, has been described in seven studies. The studies provide some empirical evidence that testosterone-lowering drugs reduce sexual activity for patients with PeD or CSBD, but the body of evidence is meager. There is a need for studies using larger samples, specific criteria for inclusion, longer follow-up periods, and standardized outcome measures with adherence to international reporting guidelines.

show abstract

Benperidol for schizophrenia

Cited by 3 publications

References 35 publications

Piperidine: A Versatile Heterocyclic Ring for Developing Monoamine Oxidase Inhibitors

Piperidine: A Versatile Heterocyclic Ring for Developing Monoamine Oxidase Inhibitors

Benperidol for schizophrenia

Pharmacological Treatment for Pedophilic Disorder and Compulsive Sexual Behavior Disorder: A Review

Contact Info

Product

Resources

About